{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:41:08Z","timestamp":1779889268177,"version":"3.53.1"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40257-018-0380-7","type":"journal-article","created":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T09:10:00Z","timestamp":1535793000000},"page":"805-819","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3188-3622","authenticated-orcid":false,"given":"Adriana T.","family":"Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Geskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,1]]},"reference":[{"issue":"7","key":"380_CR1","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archderm.143.7.854","volume":"143","author":"VD Criscione","year":"2007","unstructured":"Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973\u20132002. Arch Dermatol. 2007;143(7):854\u20139.","journal-title":"Arch Dermatol"},{"issue":"6","key":"380_CR2","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/bjd.12909","volume":"170","author":"JJ Scarisbrick","year":"2014","unstructured":"Scarisbrick JJ, et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now? Br J Dermatol. 2014;170(6):1226\u201336.","journal-title":"Br J Dermatol"},{"issue":"4","key":"380_CR3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaad.2017.05.036","volume":"77","author":"AR Mangold","year":"2017","unstructured":"Mangold AR, et al. Early clinical manifestations of Sezary syndrome: a multicenter retrospective cohort study. J Am Acad Dermatol. 2017;77(4):719\u201327.","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"380_CR4","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"EA Olsen","year":"2011","unstructured":"Olsen EA, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598\u2013607.","journal-title":"J Clin Oncol"},{"issue":"7","key":"380_CR5","first-page":"857","volume":"139","author":"YH Kim","year":"2003","unstructured":"Kim YH, et al. Long-term outcome of 525 patients with mycosis fungoides and s\u00e9zary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857\u201366.","journal-title":"Arch Dermatol"},{"issue":"11","key":"380_CR6","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/archderm.1996.03890350051009","volume":"132","author":"YH Kim","year":"1996","unstructured":"Kim YH, et al. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol. 1996;132(11):1309\u201313.","journal-title":"Arch Dermatol."},{"issue":"6","key":"380_CR7","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"E Olsen","year":"2007","unstructured":"Olsen E, et al. Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713\u201322.","journal-title":"Blood"},{"issue":"32","key":"380_CR8","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","volume":"33","author":"JJ Scarisbrick","year":"2015","unstructured":"Scarisbrick JJ, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and s\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33(32):3766\u201373.","journal-title":"J Clin Oncol"},{"issue":"13","key":"380_CR9","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.ejca.2013.04.018","volume":"49","author":"EC Benton","year":"2013","unstructured":"Benton EC, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer. 2013;49(13):2859\u201368.","journal-title":"Eur J Cancer"},{"issue":"7","key":"380_CR10","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2011-08-376319","volume":"119","author":"MF Benner","year":"2012","unstructured":"Benner MF, et al. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood. 2012;119(7):1643\u20139.","journal-title":"Blood"},{"key":"380_CR11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","volume":"77","author":"Franz Trautinger","year":"2017","unstructured":"Trautinger F, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014update 2017. Eur J Cancer. 2017;77(Suppl C):57\u201374.","journal-title":"European Journal of Cancer"},{"issue":"5","key":"380_CR12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1080\/09546634.2017.1412064","volume":"29","author":"L Geskin","year":"2018","unstructured":"Geskin L, Malone DC. An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma. J Dermatol Treat. 2018;29(5):522\u201330.","journal-title":"J Dermatol Treat."},{"issue":"9","key":"380_CR13","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","volume":"19","author":"M Duvic","year":"2001","unstructured":"Duvic M, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II\u2013III trial results. J Clin Oncol. 2001;19(9):2456\u201371.","journal-title":"J Clin Oncol"},{"issue":"2","key":"380_CR14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","volume":"19","author":"E Olsen","year":"2001","unstructured":"Olsen E, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19(2):376\u201388.","journal-title":"J Clin Oncol"},{"issue":"1","key":"380_CR15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.1990.8.1.155","volume":"8","author":"EC Kohn","year":"1990","unstructured":"Kohn EC, et al. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sezary syndrome. J Clin Oncol. 1990;8(1):155\u201360.","journal-title":"J Clin Oncol"},{"issue":"6","key":"380_CR16","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s12272-015-0571-1","volume":"38","author":"P Chun","year":"2015","unstructured":"Chun P. Histone deacetylase inhibitors in hematological malignancies and solid tumors. Arch Pharm Res. 2015;38(6):933\u201349.","journal-title":"Arch Pharm Res."},{"issue":"9","key":"380_CR17","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","volume":"47","author":"J Choi","year":"2015","unstructured":"Choi J, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47(9):1011\u20139.","journal-title":"Nat Genet"},{"issue":"9","key":"380_CR18","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.3370","volume":"47","author":"A Ungewickell","year":"2015","unstructured":"Ungewickell A, et al. Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2. Nat Genet. 2015;47(9):1056\u201360.","journal-title":"Nat Genet"},{"issue":"17","key":"380_CR19","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1200\/JCO.2005.11.353","volume":"23","author":"R Doorn van","year":"2005","unstructured":"van Doorn R, et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol. 2005;23(17):3886\u201396.","journal-title":"J Clin Oncol"},{"issue":"1","key":"380_CR20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000018423","volume":"201","author":"MM Morales Suarez-Varela","year":"2000","unstructured":"Morales Suarez-Varela MM, et al. Mycosis fungoides: review of epidemiological observations. Dermatology. 2000;201(1):21\u20138.","journal-title":"Dermatology"},{"issue":"2","key":"380_CR21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jaad.2009.11.692","volume":"64","author":"ED Mirvish","year":"2011","unstructured":"Mirvish ED, Pomerantz RG, Geskin LJ. Infectious agents in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2011;64(2):423\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"5017","key":"380_CR22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1126\/science.1857968","volume":"253","author":"WW Hall","year":"1991","unstructured":"Hall WW, et al. Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides. Science. 1991;253(5017):317\u201320.","journal-title":"Science"},{"issue":"6","key":"380_CR23","first-page":"1327.e1-1327.e1","volume":"67","author":"Nathalie Stutz","year":"2012","unstructured":"Stutz N, Johnson RD, Wood GS. The Fas apoptotic pathway in cutaneous T-cell lymphomas: Frequent expression of phenotypes associated with resistance to apoptosis. J Am Acad Dermatol. 2012;67(6):1327.e1\u20131327.e10.","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"9","key":"380_CR24","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1182\/blood-2007-08-109074","volume":"111","author":"E Contassot","year":"2008","unstructured":"Contassot E, et al. Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in S\u00e9zary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression. Blood. 2008;111(9):4780\u20137.","journal-title":"Blood"},{"issue":"3","key":"380_CR25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ijc.24064","volume":"124","author":"S Fulda","year":"2009","unstructured":"Fulda S. Tumor resistance to apoptosis. Int J Cancer. 2009;124(3):511\u20135.","journal-title":"Int J Cancer"},{"issue":"Pt 2","key":"380_CR26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1242\/jcs.01610","volume":"118","author":"I Lavrik","year":"2005","unstructured":"Lavrik I, Golks A, Krammer PH. Death receptor signaling. J Cell Sci. 2005;118(Pt 2):265\u20137.","journal-title":"J Cell Sci"},{"issue":"11","key":"380_CR27","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nrm1496","volume":"5","author":"SJ Riedl","year":"2004","unstructured":"Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 2004;5(11):897\u2013907.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"380_CR28","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/jid.2008.309","volume":"129","author":"J Wu","year":"2009","unstructured":"Wu J, et al. Low FAS\/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Investig Dermatol. 2009;129(5):1165\u201373.","journal-title":"J Investig Dermatol."},{"issue":"10","key":"380_CR29","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1038\/sj.jid.5700868","volume":"127","author":"FK Braun","year":"2007","unstructured":"Braun FK, et al. Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. J Invest Dermatol. 2007;127(10):2425\u201337.","journal-title":"J Invest Dermatol."},{"issue":"3","key":"380_CR30","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1182\/blood-2002-11-3574","volume":"102","author":"L Tracey","year":"2003","unstructured":"Tracey L, et al. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood. 2003;102(3):1042\u201350.","journal-title":"Blood"},{"issue":"1","key":"380_CR31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/excr.1999.4670","volume":"253","author":"C Schindler","year":"1999","unstructured":"Schindler C. Cytokines and JAK-STAT signaling. Exp Cell Res. 1999;253(1):7\u201314.","journal-title":"Exp Cell Res"},{"issue":"13","key":"380_CR32","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1073\/pnas.94.13.6764","volume":"94","author":"M Nielsen","year":"1997","unstructured":"Nielsen M, et al. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A. 1997;94(13):6764\u20139.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"17","key":"380_CR33","doi-asserted-by":"crossref","first-page":"9148","DOI":"10.1073\/pnas.93.17.9148","volume":"93","author":"Q Zhang","year":"1996","unstructured":"Zhang Q, et al. Activation of Jak\/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA. 1996;93(17):9148\u201353.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"5","key":"380_CR34","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/sj.leu.2402093","volume":"15","author":"KW Eriksen","year":"2001","unstructured":"Eriksen KW, et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia. 2001;15(5):787\u201393.","journal-title":"Leukemia"},{"issue":"9","key":"380_CR35","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1172\/JCI0215650","volume":"109","author":"DE Levy","year":"2002","unstructured":"Levy DE, Lee CK. What does Stat3 do? J Clin Invest. 2002;109(9):1143\u20138.","journal-title":"J Clin Invest."},{"issue":"7","key":"380_CR36","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.leu.2403385","volume":"18","author":"VH Sommer","year":"2004","unstructured":"Sommer VH, et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia. 2004;18(7):1288\u201395.","journal-title":"Leukemia"},{"issue":"4","key":"380_CR37","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood.V97.4.1056","volume":"97","author":"C Brender","year":"2001","unstructured":"Brender C, et al. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood. 2001;97(4):1056\u201362.","journal-title":"Blood"},{"issue":"13","key":"380_CR38","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1182\/blood-2013-05-504308","volume":"123","author":"JP Vaque","year":"2014","unstructured":"Vaque JP, et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood. 2014;123(13):2034\u201343.","journal-title":"Blood"},{"issue":"3","key":"380_CR39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.4161\/cc.9.3.10543","volume":"9","author":"AE Johnsson","year":"2010","unstructured":"Johnsson AE, Wright AP. The role of specific HAT-HDAC interactions in transcriptional elongation. Cell Cycle. 2010;9(3):467\u201371.","journal-title":"Cell Cycle"},{"issue":"1","key":"380_CR40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2012.06.008","volume":"22","author":"JS You","year":"2012","unstructured":"You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell. 2012;22(1):9\u201320.","journal-title":"Cancer Cell"},{"issue":"15","key":"380_CR41","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","volume":"92","author":"PA Marks","year":"2000","unstructured":"Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92(15):1210\u20136.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"380_CR42","first-page":"721","volume":"2","author":"JA Plumb","year":"2003","unstructured":"Plumb JA, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2003;2(8):721\u20138.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"380_CR43","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.0022-202X.2005.23925.x","volume":"125","author":"C Zhang","year":"2005","unstructured":"Zhang C, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol. 2005;125(5):1045\u201352.","journal-title":"J Invest Dermatol."},{"issue":"17","key":"380_CR44","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2005.16.600","volume":"23","author":"KN Bhalla","year":"2005","unstructured":"Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol. 2005;23(17):3971\u201393.","journal-title":"J Clin Oncol"},{"issue":"5","key":"380_CR45","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4161\/cc.4.5.1690","volume":"4","author":"AR Robbins","year":"2005","unstructured":"Robbins AR, et al. Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle. 2005;4(5):717\u201326.","journal-title":"Cell Cycle"},{"issue":"11","key":"380_CR46","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1158\/0008-5472.CAN-09-3028","volume":"70","author":"C Conti","year":"2010","unstructured":"Conti C, et al. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res. 2010;70(11):4470\u201380.","journal-title":"Cancer Res"},{"key":"380_CR47","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1038\/cddis.2013.9","volume":"4","author":"JE Bolden","year":"2013","unstructured":"Bolden JE, et al. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis. 2013;4:e519.","journal-title":"Cell Death Dis."},{"issue":"12","key":"380_CR48","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1517\/13543784.14.12.1497","volume":"14","author":"PA Marks","year":"2005","unstructured":"Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs. 2005;14(12):1497\u2013511.","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"380_CR49","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/jid.2011.481","volume":"132","author":"Y Qin","year":"2012","unstructured":"Qin Y, et al. Deep-sequencing analysis reveals that the miR-199a2\/214 cluster within DNM3os represents the vast majority of aberrantly expressed microRNAs in Sezary syndrome. J Invest Dermatol. 2012;132(5):1520\u20132.","journal-title":"J Invest Dermatol."},{"issue":"10","key":"380_CR50","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1182\/blood-2014-01-548578","volume":"123","author":"A Mishra","year":"2014","unstructured":"Mishra A, Garzon R. The (miR)e of CTCL. Blood. 2014;123(10):1438.","journal-title":"Blood"},{"issue":"87","key":"380_CR51","first-page":"71","volume":"16","author":"HK Wong","year":"2013","unstructured":"Wong HK. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma. Discov Med. 2013;16(87):71\u20138.","journal-title":"Discov Med."},{"issue":"6","key":"380_CR52","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.12717","volume":"170","author":"G Ferrara","year":"2014","unstructured":"Ferrara G, et al. A specific DNA methylation profile correlates with a high risk of disease progression in stage I classical (Alibert-Bazin type) mycosis fungoides. Br J Dermatol. 2014;170(6):1266\u201375.","journal-title":"Br J Dermatol"},{"issue":"4","key":"380_CR53","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/jid.2009.301","volume":"130","author":"CL Jones","year":"2010","unstructured":"Jones CL, et al. Downregulation of fas gene expression in s\u00e9zary syndrome is associated with promoter hypermethylation. J Investig Dermatol. 2010;130(4):1116\u201325.","journal-title":"J Investig Dermatol."},{"issue":"2","key":"380_CR54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000080999","volume":"67","author":"T Nagasawa","year":"2004","unstructured":"Nagasawa T, et al. Fas gene mutations in mycosis fungoides: analysis of laser capture-microdissected specimens from cutaneous lesions. Oncology. 2004;67(2):130\u20134.","journal-title":"Oncology."},{"issue":"6","key":"380_CR55","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1046\/j.1523-1747.2002.01794.x","volume":"118","author":"O Dereure","year":"2002","unstructured":"Dereure O, et al. Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin. J Invest Dermatol. 2002;118(6):949\u201356.","journal-title":"J Invest Dermatol."},{"issue":"12","key":"380_CR56","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-08-2785","volume":"15","author":"HM Prince","year":"2009","unstructured":"Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res. 2009;15(12):3958\u201369.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"380_CR57","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.bcp.2007.04.007","volume":"74","author":"KB Glaser","year":"2007","unstructured":"Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol. 2007;74(5):659\u201371.","journal-title":"Biochem Pharmacol"},{"issue":"32","key":"380_CR58","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","volume":"27","author":"RL Piekarz","year":"2009","unstructured":"Piekarz RL, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"380_CR59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205\u201316.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"380_CR60","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.","journal-title":"J Clin Oncol"},{"issue":"1","key":"380_CR61","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/bjh.13400","volume":"170","author":"SE Bates","year":"2015","unstructured":"Bates SE, et al. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data. Br J Haematol. 2015;170(1):96\u2013109.","journal-title":"Br J Haematol"},{"issue":"29","key":"380_CR62","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","volume":"28","author":"SJ Whittaker","year":"2010","unstructured":"Whittaker SJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485\u201391.","journal-title":"J Clin Oncol"},{"key":"380_CR63","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1749-6632.2001.tb03719.x","volume":"941","author":"P Heald","year":"2001","unstructured":"Heald P. Clinical trials and efficacy assessment in the therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci. 2001;941:155\u201365.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"380_CR64","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archderm.138.1.42","volume":"138","author":"SR Stevens","year":"2002","unstructured":"Stevens SR, et al. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Arch Dermatol. 2002;138(1):42\u20138.","journal-title":"Arch Dermatol"},{"issue":"6","key":"380_CR65","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","volume":"316","author":"R Edelson","year":"1987","unstructured":"Edelson R, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med. 1987;316(6):297\u2013303.","journal-title":"N Engl J Med."},{"issue":"11","key":"380_CR66","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.clml.2016.08.009","volume":"16","author":"F Foss","year":"2016","unstructured":"Foss F, et al. clinical efficacy of romidepsin in tumor stage and folliculotropic mycosis fungoides. Clin Lymphoma Myeloma Leuk. 2016;16(11):637\u201343.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"10","key":"380_CR67","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3109\/10428194.2015.1014360","volume":"56","author":"EJ Kim","year":"2015","unstructured":"Kim EJ, et al. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma. 2015;56(10):2847\u201354.","journal-title":"Leuk Lymphoma."},{"issue":"2","key":"380_CR68","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/10428194.2012.711829","volume":"54","author":"YH Kim","year":"2013","unstructured":"Kim YH, et al. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. Leuk Lymphoma. 2013;54(2):284\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"380_CR69","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1080\/10428194.2017.1361022","volume":"59","author":"M Duvic","year":"2018","unstructured":"Duvic M, et al. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk Lymphoma. 2018;59(4):800\u201387.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"380_CR70","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","volume":"109","author":"M Duvic","year":"2007","unstructured":"Duvic M, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31\u20139.","journal-title":"Blood"},{"issue":"21","key":"380_CR71","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","volume":"25","author":"EA Olsen","year":"2007","unstructured":"Olsen EA, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109\u201315.","journal-title":"J Clin Oncol"},{"issue":"22","key":"380_CR72","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1182\/blood.V114.22.1709.1709","volume":"114","author":"M Duvic","year":"2009","unstructured":"Duvic M, et al. The systemic effects of vorinostat in patients (Pts) with cutaneous T-cell lymphoma (CTCL): post-hoc analyses in pts with high blood tumor burden. Blood. 2009;114(22):1709.","journal-title":"Blood"},{"issue":"6","key":"380_CR73","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3816\/CLM.2009.n.082","volume":"9","author":"M Duvic","year":"2009","unstructured":"Duvic M, et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2009;9(6):412\u20136.","journal-title":"Clin Lymphoma Myeloma."},{"issue":"Suppl 1","key":"380_CR74","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood.V130.Suppl_1.817.817","volume":"130","author":"YH Kim","year":"2017","unstructured":"Kim YH, et al. Anti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL): results from the phase III MAVORIC study. Blood. 2017;130(Suppl 1):817.","journal-title":"Blood"},{"issue":"6","key":"380_CR75","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","volume":"168","author":"F Foss","year":"2015","unstructured":"Foss F, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015;168(6):811\u20139.","journal-title":"Br J Haematol"},{"issue":"5","key":"380_CR76","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386.","journal-title":"J Clin Oncol"},{"issue":"2","key":"380_CR77","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejca.2012.08.017","volume":"49","author":"M Duvic","year":"2013","unstructured":"Duvic M, et al. Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer. 2013;49(2):386\u201394.","journal-title":"Eur J Cancer"},{"issue":"15 Suppl","key":"380_CR78","doi-asserted-by":"crossref","first-page":"8525","DOI":"10.1200\/jco.2014.32.15_suppl.8525","volume":"32","author":"YH Kim","year":"2014","unstructured":"Kim YH, et al. A phase 1b study in cutaneous T-cell lymphoma (CTCL) with the novel topically applied skin-restricted histone deacteylase inhibitor (HDAC-i) SHP-141. J Clin Oncol. 2014;32(15 Suppl):8525.","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"380_CR79","doi-asserted-by":"crossref","first-page":"7562","DOI":"10.1200\/JCO.2016.34.15_suppl.7562","volume":"34","author":"M Duvic","year":"2016","unstructured":"Duvic M, et al. A phase 2 randomized study of SHAPE Gel (SHP-141) in patients with early-stage cutaneous T-cell lymphoma: interim results. J Clin Oncol. 2016;34(15 Suppl):7562.","journal-title":"J Clin Oncol"},{"issue":"19","key":"380_CR80","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-13-0735","volume":"19","author":"AT Brunetto","year":"2013","unstructured":"Brunetto AT, et al. First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2013;19(19):5494\u2013504.","journal-title":"Clin Cancer Res"},{"key":"380_CR81","unstructured":"4SC AG. Resminostat for maintenance treatment of patients with advanced stage mycosis fungoides (MF) or s\u00e9zary syndrome (SS) (RESMAIN). 22 Nov 2017 [cited 8 Jan 2018]. ClinicalTrials.gov identifier: NCT02953301. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02953301 . Accessed 15 Feb 2018."},{"issue":"17","key":"380_CR82","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","volume":"23","author":"WK Kelly","year":"2005","unstructured":"Kelly WK, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23(17):3923\u201331.","journal-title":"J Clin Oncol"},{"issue":"10 Pt 1","key":"380_CR83","first-page":"3578","volume":"9","author":"WK Kelly","year":"2003","unstructured":"Kelly WK, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003;9(10 Pt 1):3578\u201388.","journal-title":"Clin Cancer Res"},{"issue":"16 Suppl","key":"380_CR84","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1200\/jco.2005.23.16_suppl.3106","volume":"23","author":"T Fischer","year":"2005","unstructured":"Fischer T, et al. Results of cardiac monitoring during phase I trials of a novel histone deacetylase (HDAC) inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies. J Clin Oncol. 2005;23(16 Suppl):3106.","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"380_CR85","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1200\/jco.2005.23.16_suppl.3131","volume":"23","author":"EK Rowinsky","year":"2005","unstructured":"Rowinsky EK, et al. Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies. J Clin Oncol. 2005;23(16 Suppl):3131.","journal-title":"J Clin Oncol"},{"issue":"11","key":"380_CR86","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1158\/1078-0432.CCR-13-0109","volume":"19","author":"AM Noonan","year":"2013","unstructured":"Noonan AM, et al. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel. Clin Cancer Res. 2013;19(11):3095\u2013104.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"380_CR87","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1182\/blood.V114.22.3709.3709","volume":"114","author":"C Cabell","year":"2009","unstructured":"Cabell C, et al. Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin. Blood. 2009;114(22):3709.","journal-title":"Blood"},{"issue":"5","key":"380_CR88","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11886-004-0041-8","volume":"6","author":"DL Wolbrette","year":"2004","unstructured":"Wolbrette DL. Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death. Curr Cardiol Rep. 2004;6(5):379\u201384.","journal-title":"Curr Cardiol Rep."},{"issue":"1","key":"380_CR89","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/157488610789869247","volume":"5","author":"ML Ponte","year":"2010","unstructured":"Ponte ML, Keller GA, Di Girolamo G. Mechanisms of drug induced QT interval prolongation. Curr Drug Saf. 2010;5(1):44\u201353.","journal-title":"Curr Drug Saf."},{"issue":"14","key":"380_CR90","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1101\/gad.1563807","volume":"21","author":"RL Montgomery","year":"2007","unstructured":"Montgomery RL, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 2007;21(14):1790\u2013802.","journal-title":"Genes Dev"},{"issue":"6","key":"380_CR91","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1080\/10428190290026367","volume":"43","author":"M Morgan","year":"2002","unstructured":"Morgan M, Maloney D, Duvic M. Hypomagnesemia and hypocalcemia in mycosis fungoides: a retrospective case series. Leuk Lymphoma. 2002;43(6):1297\u2013302.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"380_CR92","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1681\/ASN.2007070792","volume":"18","author":"CL Huang","year":"2007","unstructured":"Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol. 2007;18(10):2649\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"13","key":"380_CR93","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1158\/1078-0432.CCR-05-2689","volume":"12","author":"MH Shah","year":"2006","unstructured":"Shah MH, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2006;12(13):3997\u20134003.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"380_CR94","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3816\/CGC.2006.n.018","volume":"5","author":"WM Stadler","year":"2006","unstructured":"Stadler WM, et al. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006;5(1):57\u201360.","journal-title":"Clin Genitourin Cancer."},{"issue":"12","key":"380_CR95","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","volume":"12","author":"RL Piekarz","year":"2006","unstructured":"Piekarz RL, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006;12(12):3762\u201373.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"380_CR96","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ctrv.2006.08.006","volume":"33","author":"SJ Whittaker","year":"2007","unstructured":"Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev. 2007;33(2):146\u201360.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"380_CR97","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","volume":"7","author":"M Duvic","year":"2006","unstructured":"Duvic M, et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006;7(1):51\u20138.","journal-title":"Clin Lymphoma Myeloma."},{"issue":"12","key":"380_CR98","doi-asserted-by":"crossref","first-page":"E491","DOI":"10.1002\/ajh.24564","volume":"91","author":"W Hanel","year":"2016","unstructured":"Hanel W, et al. A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome. Am J Hematol. 2016;91(12):E491\u20135.","journal-title":"Am J Hematol"},{"issue":"8","key":"380_CR99","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/archderm.138.8.1054","volume":"138","author":"KR Suchin","year":"2002","unstructured":"Suchin KR, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol. 2002;138(8):1054\u201360.","journal-title":"Arch Dermatol"},{"issue":"18","key":"380_CR100","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","volume":"18","author":"R Talpur","year":"2012","unstructured":"Talpur R, et al. Long term outcomes of 1263 patients with Mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18(18):5051\u201360.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"380_CR101","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769\u201384.","journal-title":"Nat Rev Drug Discov."},{"issue":"3","key":"380_CR102","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pharmthera.2014.04.004","volume":"143","author":"P Bose","year":"2014","unstructured":"Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther. 2014;143(3):323\u201336.","journal-title":"Pharmacol Ther"},{"issue":"8","key":"380_CR103","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3109\/10428194.2012.656625","volume":"53","author":"R Dummer","year":"2012","unstructured":"Dummer R, et al. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor\/retinoid X receptor activation by histone deacetylase inhibition. Leuk Lymphoma. 2012;53(8):1501\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"380_CR104","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jaad.2008.11.889","volume":"61","author":"JM Gardner","year":"2009","unstructured":"Gardner JM, et al. A novel regimen of vorinostat with interferon gamma for refractory S\u00e9zary syndrome. J Am Acad Dermatol. 2009;61(1):112\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"380_CR105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1548-5315(11)70386-2","volume":"7","author":"L Geskin","year":"2010","unstructured":"Geskin L. Vorinostat in combination therapy for cutaneous T-cell lymphoma: a first year of clinical experience at a single center. Community Oncology. 2010;7(1):31\u20136.","journal-title":"Community Oncology."},{"issue":"1","key":"380_CR106","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.jaad.2011.06.043","volume":"68","author":"S Samimi","year":"2013","unstructured":"Samimi S, et al. Romidepsin and interferon gamma: a novel combination for refractory cutaneous T-cell lymphoma. J Am Acad Dermatol. 2013;68(1):e5\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"380_CR107","first-page":"3","volume":"12","author":"J Vesely","year":"1965","unstructured":"Vesely J, Sorm F. The cytologic and the metabolic effects of a new antileukemic analogue 5-azacytidine in normal mice followed autoradiographically with tritium. Neoplasma. 1965;12:3\u20139.","journal-title":"Neoplasma"},{"issue":"3","key":"380_CR108","doi-asserted-by":"crossref","first-page":"587","DOI":"10.18632\/oncotarget.1782","volume":"5","author":"H Li","year":"2014","unstructured":"Li H, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014;5(3):587\u201398.","journal-title":"Oncotarget."},{"issue":"8","key":"380_CR109","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-15-1435","volume":"22","author":"S Rozati","year":"2016","unstructured":"Rozati S, et al. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL. Clin Cancer Res. 2016;22(8):2020\u201331.","journal-title":"Clin Cancer Res"},{"key":"380_CR110","unstructured":"Celgene. Romidepsin Plus Oral 5-Azacitidine in Relapsed\/Refractory Lymphoid Malignancies. 28 Aug 2017 [cited 17 Jan 2018]. ClinicalTrials.gov identifier: NCT01998035. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01998035 . Accessed 3 Feb 2018."},{"issue":"1","key":"380_CR111","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1365-2133.2012.10905.x","volume":"167","author":"OE Akilov","year":"2012","unstructured":"Akilov OE, et al. Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions. Br J Dermatol. 2012;167(1):194\u20137.","journal-title":"Br J Dermatol"},{"issue":"11","key":"380_CR112","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1182\/blood.V110.11.4482.4482","volume":"110","author":"LJ Geskin","year":"2007","unstructured":"Geskin LJ. Vorinostat in combination with other agents for therapy of cutaneous T-cell lymphomas: a case series. Blood. 2007;110(11):4482.","journal-title":"Blood"},{"issue":"2","key":"380_CR113","first-page":"165","volume":"139","author":"YH Kim","year":"2003","unstructured":"Kim YH, et al. Topical nitrogen mustard in the management of mycosis fungoides: update of the stanford experience. Arch Dermatol. 2003;139(2):165\u201373.","journal-title":"Arch Dermatol"},{"issue":"11","key":"380_CR114","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.1987.5.11.1796","volume":"5","author":"RT Hoppe","year":"1987","unstructured":"Hoppe RT, et al. Mycosis fungoides: management with topical nitrogen mustard. J Clin Oncol. 1987;5(11):1796\u2013803.","journal-title":"J Clin Oncol"},{"issue":"6","key":"380_CR115","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1747-0285.2010.00969.x","volume":"75","author":"AM Galea","year":"2010","unstructured":"Galea AM, Murray V. The influence of chromatin structure on DNA damage induced by nitrogen mustard and cisplatin analogues. Chem Biol Drug Des. 2010;75(6):578\u201389.","journal-title":"Chem Biol Drug Des"},{"issue":"7","key":"380_CR116","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.3109\/10428194.2014.995649","volume":"56","author":"BON Dulmage","year":"2015","unstructured":"Dulmage BON, et al. Novel therapeutic combination demonstrates more than additive effects in cutaneous T-cell lymphoma. Leuk Lymphoma. 2015;56(7):2225\u20137.","journal-title":"Leuk Lymphoma."},{"key":"380_CR117","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2050-7771-2-16","volume":"2","author":"F Foss","year":"2014","unstructured":"Foss F, et al. Tolerability to romidepsin in patients with relapsed\/refractory T-cell lymphoma. Biomark Res. 2014;2:16.","journal-title":"Biomark Res."},{"issue":"1","key":"380_CR118","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood.V89.1.32","volume":"89","author":"CM Jackow","year":"1997","unstructured":"Jackow CM, et al. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood. 1997;89(1):32\u201340.","journal-title":"Blood"},{"issue":"6","key":"380_CR119","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jaad.2008.08.030","volume":"59","author":"V Nguyen","year":"2008","unstructured":"Nguyen V, et al. Cutaneous T-cell lymphoma and Staphylococcus aureus colonization. J Am Acad Dermatol. 2008;59(6):949\u201352.","journal-title":"J Am Acad Dermatol"},{"key":"380_CR120","unstructured":"Istodax (romidepsin) [package insert] 2016. http:\/\/www.istodax.com\/wp-content\/uploads\/ISTODAX_PackageInsert.pdf . Accessed 15 Jan 2018."},{"key":"380_CR121","unstructured":"Zolinza (vorinostat) [package insert] 2015. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zolinza\/zolinza_pi.pdf . Accessed 15 Jan 2018."},{"key":"380_CR122","unstructured":"Beleodaq (belinostat) [package insert] 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206256lbl.pdf . Accessed 15 Jan 2018."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-018-0380-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0380-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0380-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T03:23:01Z","timestamp":1661916181000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-018-0380-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":122,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["380"],"URL":"https:\/\/doi.org\/10.1007\/s40257-018-0380-7","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,1]]},"assertion":[{"value":"1 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to assist in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Susan Bates has been a principal investigator for romidepsin and belinostat studies, and received research funding from Celgene, Inc. She has also participated in advisory boards for Celgene and Mundipharma, and received honoraria for participating in these advisory boards. Larisa Geskin and Adriana Lopez have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}